Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

NCT02802098 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Bevacizumab-alone Maintenance Treatment Progression

Interventions

DRUG: Durvalumab
DRUG: Bevacizumab

Sponsor

Centro Nacional de Investigaciones Oncologicas CARLOS III

Collaborators

[object Object]